These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 12065865)
41. Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth. Bohlen H; Thielemanns K; Tesch H; Engert A; Wolf HJ; van Camp B; Urbain J; Diehl V Cytokines Mol Ther; 1996 Dec; 2(4):231-8. PubMed ID: 9384709 [TBL] [Abstract][Full Text] [Related]
42. Induction of cellular immune responses in patients with stage-I multiple myeloma after vaccination with autologous idiotype-pulsed dendritic cells. Röllig C; Schmidt C; Bornhäuser M; Ehninger G; Schmitz M; Auffermann-Gretzinger S J Immunother; 2011 Jan; 34(1):100-6. PubMed ID: 21150718 [TBL] [Abstract][Full Text] [Related]
43. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma. Gadri Z; Kukulansky T; Bar-Or E; Haimovich J; Hollander N J Immunother; 2009 May; 32(4):333-40. PubMed ID: 19342972 [TBL] [Abstract][Full Text] [Related]
44. Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials. Park HJ; Neelapu SS Br J Haematol; 2008 Jun; 142(2):179-91. PubMed ID: 18422783 [TBL] [Abstract][Full Text] [Related]
45. The role of idiotype vaccines in the treatment of human B-cell malignancies. Bendandi M Expert Rev Vaccines; 2004 Apr; 3(2):163-70. PubMed ID: 15056042 [TBL] [Abstract][Full Text] [Related]
46. Active immunotherapy: current state of the art in vaccine approaches for NHL. Palomba ML Curr Oncol Rep; 2012 Oct; 14(5):433-40. PubMed ID: 22843515 [TBL] [Abstract][Full Text] [Related]
47. Active immunotherapy of multiple myeloma. Houet L; Veelken H Eur J Cancer; 2006 Jul; 42(11):1653-60. PubMed ID: 16797966 [TBL] [Abstract][Full Text] [Related]
48. Accomplishments and perspectives of immunological interventions in lymphoproliferative disorders. Milosević DB J Exp Clin Cancer Res; 2004 Mar; 23(1):9-13. PubMed ID: 15149145 [TBL] [Abstract][Full Text] [Related]
49. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. Kwak LW; Campbell MJ; Czerwinski DK; Hart S; Miller RA; Levy R N Engl J Med; 1992 Oct; 327(17):1209-15. PubMed ID: 1406793 [TBL] [Abstract][Full Text] [Related]
50. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model. Kwak LW; Campbell M; Levy R Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139 [TBL] [Abstract][Full Text] [Related]
51. Antitumor vaccination: where we stand. Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658 [TBL] [Abstract][Full Text] [Related]
52. Vaccination against B-cell chronic lymphocytic leukemia with trioma cells: preclinical evaluation. Wahl U; Nössner E; Kronenberger K; Gangnus R; Pohla H; Staege MS; Kolb HJ; Hallek M; Mocikat R Clin Cancer Res; 2003 Sep; 9(11):4240-6. PubMed ID: 14519651 [TBL] [Abstract][Full Text] [Related]
53. DNA vaccine for cancer immunotherapy. Yang B; Jeang J; Yang A; Wu TC; Hung CF Hum Vaccin Immunother; 2014; 10(11):3153-64. PubMed ID: 25625927 [TBL] [Abstract][Full Text] [Related]
54. Dendritic cell-based immunotherapy for the treatment of hematological malignancies. Büchler T; Michalek J; Kovarova L; Musilova R; Hajek R Hematology; 2003 Apr; 8(2):97-104. PubMed ID: 12745659 [TBL] [Abstract][Full Text] [Related]
55. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells. Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465 [TBL] [Abstract][Full Text] [Related]
56. Chemically linked phage idiotype vaccination in the murine B cell lymphoma 1 model. Roehnisch T; Then C; Nagel W; Blumenthal C; Braciak T; Donzeau M; Böhm T; Bourquin C; Oduncu F J Transl Med; 2013 Oct; 11():267. PubMed ID: 24152874 [TBL] [Abstract][Full Text] [Related]
57. Anti-idiotypic DNA vaccines for B-cell lymphoma therapy. Benvenuti F; Cesco-Gaspere M; Burrone OR Front Biosci; 2002 Jan; 7():d228-34. PubMed ID: 11779689 [TBL] [Abstract][Full Text] [Related]
58. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. Campbell MJ; Carroll W; Kon S; Thielemans K; Rothbard JB; Levy S; Levy R J Immunol; 1987 Oct; 139(8):2825-33. PubMed ID: 3498771 [TBL] [Abstract][Full Text] [Related]
59. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. Curti A; Tosi P; Comoli P; Terragna C; Ferri E; Cellini C; Massaia M; D'Addio A; Giudice V; Di Bello C; Cavo M; Conte R; Gugliotta G; Baccarani M; Lemoli RM Br J Haematol; 2007 Nov; 139(3):415-24. PubMed ID: 17910631 [TBL] [Abstract][Full Text] [Related]